Emerging from their burrow: Hedgehog pathway inhibitors for cancer

References

• Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980;287:795–801.
   PubMed Web of Science ®Google Scholar
• Echelard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell. 1993;75:1417–1430.
   PubMed Web of Science ®Google Scholar
• Alman BA. The role of hedgehog signalling in skeletal health and disease. Nat Rev Rheumatol. 2015;11:552–560.
   PubMed Web of Science ®Google Scholar
• Cheng SY, Bishop JM. Suppressor of fused represses Gli-mediated transcription by recruiting the SAP18-mSin3 corepressor complex. Proc Natl Acad Sci U S A. 2002;99:5442–5447.
   PubMed Web of Science ®Google Scholar
• Kogerman P, Grimm T, Kogerman L, et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat Cell Biol. 1999;1:312–319.
   PubMed Web of Science ®Google Scholar
• Paces-Fessy M, Boucher D, Petit E, et al. The negative regulator of Gli, Suppressor of fused (Sufu), interacts with SAP18, Galectin3 and other nuclear proteins. Biochem J. 2004;378:353–362.
   PubMed Web of Science ®Google Scholar
• Ruiz I Altaba A. Catching a Gli-mpse of Hedgehog. Cell. 1997;90:193–196.
   PubMed Web of Science ®Google Scholar
• Hui C-C, Angers S. Gli proteins in development and disease. Annu Rev Cell Dev Biol. 2011;27:513–537.
   PubMed Web of Science ®Google Scholar
• Scales SJ, De Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009;30:303–312.
   PubMed Web of Science ®Google Scholar
• Stecca B, Ruiz IAA. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol. 2010;2:84–95.
   PubMed Web of Science ®Google Scholar
• Bora-Singhal N, Perumal D, Nguyen J, et al. Gli1-mediated regulation of Sox2 facilitates self-renewal of stem-like cells and confers resistance to EGFR inhibitors in non-small cell lung cancer. Neoplasia. 2015;17:538–551.
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol. 2009;35:187–192.
   PubMed Web of Science ®Google Scholar
• Sheng T, Chi S, Zhang X, et al. Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal. J Biol Chem. 2006;281:9–12.
   PubMed Web of Science ®Google Scholar
• Jia J, Amanai K, Wang G, et al. Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature. 2002;416:548–552.
   PubMed Web of Science ®Google Scholar
• Cortés CR, Metzis V, Wicking C. Unmasking the ciliopathies: craniofacial defects and the primary cilium. Wiley Interdiscip Rev Dev Biol. 2015;4:637–653.
   PubMed Web of Science ®Google Scholar
• Liu A, Wang B, Niswander LA. Mouse intraflagellar transport proteins regulate both the activator and repressor functions of Gli transcription factors. Development. 2005;132:3103–3111.
   PubMed Web of Science ®Google Scholar
• Huangfu D, Liu A, Rakeman AS, et al. Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature. 2003;426:83–87.
   PubMed Web of Science ®Google Scholar
• Zaghloul NA, Brugmann SA. The emerging face of primary cilia. Genesis. 2011;49:231–246.
   PubMed Web of Science ®Google Scholar
• Roessler E, Belloni E, Gaudenz K, et al. Mutations in the human sonic Hedgehog gene cause holoprosencephaly. Nat Genet. 1996;14:357–360.
   PubMed Web of Science ®Google Scholar
• Rohatgi R, Milenkovic L, Scott MP. Patched1 regulates hedgehog signaling at the primary cilium. Science. 2007;317:372–376.
   PubMed Web of Science ®Google Scholar
• Corbit KC, Aanstad P, Singla V, et al. Vertebrate smoothened functions at the primary cilium. Nature. 2005;437:1018–1021.
   PubMed Web of Science ®Google Scholar
• Haycraft CJ, Banizs B, Aydin-Son Y, et al. Gli2 and Gli3 localize to cilia and require the intraflagellar transport protein polaris for processing and function. PLoS Genet. 2005;1:e53.
   PubMed Web of Science ®Google Scholar
• Robbins DJ, Fei DL, Riobo NA. The Hedgehog signal transduction network. Sci Signal. 2012;5:re6.
   PubMed Web of Science ®Google Scholar
• Nachury MV. How do cilia organize signalling cascades? Philos Trans R Soc Lond B Biol Sci. 2014;369.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ding Q, Yen C-J, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012;21:374–387.
   PubMed Web of Science ®Google Scholar
• Gan GN, Eagles J, Keysar SB, et al. Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers. Cancer Res. 2014;74:7024–7036.
   PubMed Web of Science ®Google Scholar
• Ke Z, Caiping S, Qing Z, et al. Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway. Med Oncol. 2015;32:368.
   PubMed Web of Science ®Google Scholar
• Ramaswamy B, Lu Y, Teng K-Y, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 2012;72:5048–5059.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhu G, Huang J, et al. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: a novel potential therapeutic target. Cancer Lett. 2016;370:313–323.
   PubMed Web of Science ®Google Scholar
• Srivastava RK, Kaylani SZ, Edrees N, et al. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis. Oncotarget. 2014;5:12151–12165.
   PubMed Web of Science ®Google Scholar
• Ji Z, Mei FC, Xie J, et al. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem. 2007;282:14048–14055.
   PubMed Web of Science ®Google Scholar
• Rajurkar M, De Jesus-Monge WE, Driscoll DR, et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A. 2012;109:E1038–E1047.
   PubMed Web of Science ®Google Scholar
• Nolan-Stevaux O, Lau J, Truitt ML, et al. GLI1 is regulated through smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009;23:24–36.
   PubMed Web of Science ®Google Scholar
• Dennler S, André J, Alexaki I, et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 2007;67:6981–6986.
   PubMed Web of Science ®Google Scholar
• Rao G, Pedone CA, Del Valle L, et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene. 2004;23:6156–6162.
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med. 2009;9:873–886.
   PubMed Web of Science ®Google Scholar
• Daya-Grosjean L, Couvé-Privat S. Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett. 2005;225:181–192.
   PubMed Web of Science ®Google Scholar
• Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–851.
   PubMed Web of Science ®Google Scholar
• Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14:78–81.
   PubMed Web of Science ®Google Scholar
• Kim M-Y, Park HJ, Baek S-C, et al. Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. J Dermatol Sci. 2002;29:1–9.
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998;58:1798–1803.
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152:43–51.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–2179.
   PubMed Web of Science ®Google Scholar
• Axelson M, Liu K, Jiang X, et al. U.S. food and drug administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19:2289–2293.
   PubMed Web of Science ®Google Scholar
• Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol. 2012;148:1324–1325.
   PubMedGoogle Scholar
• Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27:327–341.
   PubMed Web of Science ®Google Scholar
• Atwood SX, Sarin KY, Whitson RJ, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27:342–353.
   PubMed Web of Science ®Google Scholar
• Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9:389–397.
   PubMed Web of Science ®Google Scholar
• Li T, Liao X, Lochhead P, et al. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. Ann Surg Oncol. 2014;21:4164–4173.
   PubMed Web of Science ®Google Scholar
• Paw I, Carpenter RC, Watabe K, et al. Mechanisms regulating glioma invasion. Cancer Lett. 2015;362:1–7.
   PubMed Web of Science ®Google Scholar
• Fan HX, Wang S, Zhao H, et al. Sonic hedgehog signaling may promote invasion and metastasis of oral squamous cell carcinoma by activating MMP-9 and E-cadherin expression. Med Oncol. 2014;31:41.
   PubMed Web of Science ®Google Scholar
• Thomas ZI, Gibson W, Sexton JZ, et al. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br J Cancer. 2011;104:1575–1586.
   PubMed Web of Science ®Google Scholar
• Chung CH, Dignam JJ, Hammond ME, et al. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011;29:1326–1334.
   PubMed Web of Science ®Google Scholar
• Wellbrock J, Latuske E, Köhler J, et al. Expression of Hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects. Clin Cancer Res. 2015;21:2388–2398.
   PubMed Web of Science ®Google Scholar
• Steg AD, Katre AA, Bevis KS, et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther. 2012;11:1587–1597.
   PubMed Web of Science ®Google Scholar
• Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–273.
   PubMed Web of Science ®Google Scholar
• Cigna N, Farrokhi Moshai E, Brayer S, et al. The hedgehog system machinery controls transforming growth factor-beta-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. Am J Pathol. 2012;181:2126–2137.
   PubMed Web of Science ®Google Scholar
• Garber K. At the frontiers of lung fibrosis therapy. Nat Biotechnol. 2013;31:781–783.
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med. 2008;22:271–275.
   PubMed Web of Science ®Google Scholar
• Ginnebaugh KR, Ahmad A, Sarkar FH. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer. Expert Opin Ther Targets. 2014;18:731–745.
   PubMed Web of Science ®Google Scholar
• Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001;61:2207–2211.
   PubMed Web of Science ®Google Scholar
• Qian L-W, Mizumoto K, Urashima T, et al. Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin Cancer Res. 2002;8:1223–1227.
   PubMed Web of Science ®Google Scholar
• Wild-Bode C, Weller M, Rimner A, et al. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 2001;61:2744–2750.
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Shibata K, Kajiyama H, et al. Irradiation-induced epithelial-mesenchymal transition (EMT) related to invasive potential in endometrial carcinoma cells. Gynecol Oncol. 2007;107:500–504.
   PubMed Web of Science ®Google Scholar
• Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009;27:2059–2068.
   PubMed Web of Science ®Google Scholar
• Kim YH, Kim G, Kwon C-I, et al. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-beta1. Oncol Rep. 2014;31:1380–1388.
   PubMed Web of Science ®Google Scholar
• Steg AD, Bevis KS, Katre AA, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res. 2012;18:869–881.
   PubMed Web of Science ®Google Scholar
• De Boeck A, Narine K, De Neve W, et al. Resident and bone marrow-derived mesenchymal stem cells in head and neck squamous cell carcinoma. Oral Oncol. 2010;46:336–342.
   PubMed Web of Science ®Google Scholar
• Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A. 2007;104:4048–4053.
   PubMed Web of Science ®Google Scholar
• Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol. 2008;26:2871–2875.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Feldmann G, Suárez-Gauthier A, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009;8:310–314.
   PubMed Web of Science ®Google Scholar
• Keysar SB, Le PN, Anderson RT, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 2013;73:3381–3392.
   PubMed Web of Science ®Google Scholar
• Bowles DW, Keysar SB, Eagles JR, et al. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016;53:74–79.
   PubMed Web of Science ®Google Scholar
• Ohta H, Aoyagi K, Fukaya M, et al. Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers. Br J Cancer. 2009;100:389–398.
   PubMed Web of Science ®Google Scholar
• Isohata N, Aoyagi K, Mabuchi T, et al. Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus. Int J Cancer. 2009;125:1212–1221.
   PubMed Web of Science ®Google Scholar
• Kawamoto A, Yokoe T, Tanaka K, et al. Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep. 2012;27:51–57.
   PubMed Web of Science ®Google Scholar
• Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21:283–296.
   PubMed Web of Science ®Google Scholar
• Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–319.
   PubMed Web of Science ®Google Scholar
• Merchant AA, Matsui W. Targeting Hedgehog–a cancer stem cell pathway. Clin Cancer Res. 2010;16:3130–3140.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–1428.
   PubMed Web of Science ®Google Scholar
• Tsai JH, Donaher JL, Murphy DA, et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell. 2012;22:725–736.
   PubMed Web of Science ®Google Scholar
• Berlin J, Bendell JC, Hart LL, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013;19:258–267.
   PubMed Web of Science ®Google Scholar
• Kaye SB, Fehrenbacher L, Holloway R, et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18:6509–6518.
   PubMed Web of Science ®Google Scholar
• Tian A, Shi Q, Jiang A, et al. Injury-stimulated Hedgehog signaling promotes regenerative proliferation of Drosophila intestinal stem cells. J Cell Biol. 2015;208:807–819.
   PubMed Web of Science ®Google Scholar
• Suh HN, Han HJ. Sonic hedgehog increases the skin wound-healing ability of mouse embryonic stem cells through the microRNA 200 family. Br J Pharmacol. 2015;172:815–828.
   PubMed Web of Science ®Google Scholar
• Yang J-J, Tao H, Li J. Hedgehog signaling pathway as key player in liver fibrosis: new insights and perspectives. Expert Opin Ther Targets. 2014;18:1011–1021.
   PubMed Web of Science ®Google Scholar
• Wang S, Hyun J, Youn B, et al. Hedgehog signaling regulates the repair response in mouse liver damaged by irradiation. Radiat Res. 2013;179:69–75.
   PubMed Web of Science ®Google Scholar
• Zeng J, Aziz K, Chettiar ST, et al. Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. Int J Radiat Oncol Biol Phys. 2013;86:143–149.
   PubMed Web of Science ®Google Scholar
• Chen W, Tang T, Eastham-Anderson J, et al. Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci U S A. 2011;108:9589–9594.
   PubMed Web of Science ®Google Scholar
• Fingas CD, Bronk SF, Werneburg NW, et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54:2076–2088.
   PubMed Web of Science ®Google Scholar
• Trujillo KA, Heaphy CM, Mai M, et al. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer. 2011;129:1310–1321.
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhuang X-M, Wang Y-Y, et al. Tumor necrosis factor alpha induces myofibroblast differentiation in human tongue cancer and promotes invasiveness and angiogenesis via secretion of stromal cell-derived factor-1. Oral Oncol. 2015;51:1095–1102.
   PubMed Web of Science ®Google Scholar
• Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic Hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33:2646–2654.
   PubMed Web of Science ®Google Scholar
• Della Corte CM, Bellevicine C, Vicidomini G, et al. SMO gene amplification and activation of the Hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer. Clin Cancer Res. 2015;21:4686–4697.
   PubMed Web of Science ®Google Scholar
• Fu J, Rodova M, Nanta R, et al. NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. Neuro Oncol. 2013;15:691–706.
   PubMed Web of Science ®Google Scholar
• D’Amato C, Rosa R, Marciano R, et al. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014;111:1168–1179.
   PubMed Web of Science ®Google Scholar
• Ko AH, LoConte N, Tempero MA, et al. A phase I study of FOLFIRINOX plus IPI-926, a Hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas. 2016;45:370–375.
   PubMed Web of Science ®Google Scholar
• Akare UR, Bandaru S, Shaheen U, et al. Molecular docking approaches in identification of high affinity inhibitors of human SMO receptor. Bioinformation. 2014;10:737–742.
   PubMedGoogle Scholar
• Riedlinger D, Bahra M, Boas-Knoop S, et al. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014;21:607–615.
   PubMed Web of Science ®Google Scholar
• Zaidi AH, Komatsu Y, Kelly LA, et al. Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells. Cancer Invest. 2013;31:480–489.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Messersmith WA, Shaik MN, et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:1044–1051.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Oehler VG, Papayannidis C, et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015;2:e339–e346.
   PubMed Web of Science ®Google Scholar
• Rohner A, Spilker ME, Lam JL, et al. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective smoothened antagonist that penetrates the blood-brain barrier. Mol Cancer Ther. 2012;11:57–65.
   PubMed Web of Science ®Google Scholar
• Bender MH, Hipskind PA, Capen AR, et al. Abstract 2819: identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Cancer Research. 2011;71:2819.
   Web of Science ®Google Scholar
• Antonarakis ES, Heath EI, Smith DC, et al. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist. 2013;18:163–173.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32:745–751.
   PubMed Web of Science ®Google Scholar
• Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011;121:148–160.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Nagano S, Nagao H, et al. Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation. PLoS One. 2013;8:e69466.
   PubMed Web of Science ®Google Scholar
• Yang D, Cao F, Ye X, et al. Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia. Acta Haematol. 2013;130:260–267.
   PubMed Web of Science ®Google Scholar
• You M, Varona-Santos J, Singh S, et al. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2014;147:508–516.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Masuelli L, De Smaele E, et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget. 2016;7:9250–9270.
   PubMed Web of Science ®Google Scholar
• Wang J, Gu S, Huang J, et al. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells. BMC Cancer. 2014;14:768.
   PubMed Web of Science ®Google Scholar
• Huang L, Walter V, Hayes DN, et al. Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. Clin Cancer Res. 2014;20:1566–1575.
   PubMed Web of Science ®Google Scholar
• Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19:5576–5581.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–1178.
   PubMed Web of Science ®Google Scholar
• Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572–574.
   PubMed Web of Science ®Google Scholar
• Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266–4276.
   PubMed Web of Science ®Google Scholar
• Hwang RF, Moore TT, Hattersley MM, et al. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. Mol Cancer Res. 2012;10:1147–1157.
   PubMed Web of Science ®Google Scholar
• Duner S, Lopatko Lindman J, Ansari D, et al. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology. 2010;10:673–681.
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457–1461.
   PubMed Web of Science ®Google Scholar
• Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735–747.
   PubMed Web of Science ®Google Scholar
• Catenacci DV, Junttila MR, Karrison T, et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol. 2015;33:4284–4292.
   PubMed Web of Science ®Google Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–728.
   PubMed Web of Science ®Google Scholar
• Nanta R, Kumar D, Meeker D, et al. NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rgamma null mice by regulating Bmi-1 and microRNA-128. Oncogenesis. 2013;2:e42.
   PubMed Web of Science ®Google Scholar
• Heller E, Hurchla MA, Xiang J, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012;72:897–907.
   PubMed Web of Science ®Google Scholar
• McCann CK, Growdon WB, Kulkarni-Datar K, et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One. 2011;6:e28077.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Hatton BA, Villavicencio EH, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci U S A. 2012;109:7859–7864.
   PubMed Web of Science ®Google Scholar
• Campbell VT, Nadesan P, Ali SA, et al. Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth. Mol Cancer Ther. 2014;13:1259–1269.
   PubMed Web of Science ®Google Scholar
• Wilkinson SE, Furic L, Buchanan G, et al. Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium. Prostate. 2013;73:1810–1823.
   PubMed Web of Science ®Google Scholar
• Munchhof MJ, Li Q, Shavnya A, et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett. 2012;3:106–111.
   PubMed Web of Science ®Google Scholar
• Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388–399.
   PubMed Web of Science ®Google Scholar
• Chen B, Trang V, Lee A, et al. Posaconazole, a second-generation triazole antifungal drug, inhibits the Hedgehog signaling pathway and progression of basal cell carcinoma. Mol Cancer Ther. 2016;15:866–876.
   PubMed Web of Science ®Google Scholar
• Agyeman A, Jha BK, Mazumdar T, et al. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget. 2014;5:4492–4503.
   PubMed Web of Science ®Google Scholar
• Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002;39:3–7.
   PubMed Web of Science ®Google Scholar
• Han J-B, Sang F, Chang J-J, et al. Arsenic trioxide inhibits viability of pancreatic cancer stem cells in culture and in a xenograft model via binding to SHH-Gli. Onco Targets Ther. 2013;6:1129–1138.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–1019.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742.
   PubMed Web of Science ®Google Scholar
• Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719–734.
   PubMed Web of Science ®Google Scholar
• Barker HE, Paget JT, Khan AA, et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409–425.
   PubMed Web of Science ®Google Scholar